Cargando…
Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study
BACKGROUND: The benefits of preventive treatment on the effectiveness of migraine management have rarely been examined. This post hoc analysis investigated the impact of eptinezumab on the optimization of acute medication effectiveness using the 4-item Migraine Treatment Optimization Questionnaire (...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336038/ https://www.ncbi.nlm.nih.gov/pubmed/35902796 http://dx.doi.org/10.1186/s10194-022-01463-3 |
_version_ | 1784759459552165888 |
---|---|
author | Cady, Roger Lipton, Richard B. Buse, Dawn C. Josiassen, Mette Krog Lindsten, Annika Ettrup, Anders |
author_facet | Cady, Roger Lipton, Richard B. Buse, Dawn C. Josiassen, Mette Krog Lindsten, Annika Ettrup, Anders |
author_sort | Cady, Roger |
collection | PubMed |
description | BACKGROUND: The benefits of preventive treatment on the effectiveness of migraine management have rarely been examined. This post hoc analysis investigated the impact of eptinezumab on the optimization of acute medication effectiveness using the 4-item Migraine Treatment Optimization Questionnaire (mTOQ-4) to measure acute medication optimization over 4 weeks post-infusion. METHODS: RELIEF was a 12-week, phase 3, multicenter, parallel-group, double-blind, placebo-controlled clinical trial conducted in patients aged 18–75 years with a ≥ 1-year history of migraine and 4–15 migraine days per month in the 3 months prior to screening. Patients were randomized 1:1 to a 30-min infusion of eptinezumab 100 mg or placebo within 1–6 h of a qualifying migraine attack. The mTOQ-6 and 6-item Headache Impact Test (HIT-6) were administered at screening visit and week 4. From the mTOQ-6, we calculated the mTOQ-4 using the following items: “2-h pain free,” “24-h relief,” “able to plan,” and “feeling in control” to measure acute medication optimization. RESULTS: A total of 238 patients received eptinezumab 100 mg and 226 provided week 4 data; 242 received placebo and 232 provided week 4 data. In the eptinezumab arm, the proportion of patients with moderate/maximal optimization increased from 31.4% at baseline to 58.0% (26.6 percentage point increase) at week 4. The corresponding proportions in the placebo group were 40.5% to 50.4% (9.9 percentage point increase). Eptinezumab treatment was associated with numerically larger improvements in HIT-6 at week 4. Relative improvements with eptinezumab vs. placebo from baseline to week 4 in HIT-6 were greater in those with poor treatment optimization at baseline. CONCLUSIONS: In comparison with placebo, treatment with eptinezumab was associated with improvements in acute medication optimization as measured by mTOQ and reductions in headache impact, as measured by HIT-6. These benefits were greater in those with poor acute treatment optimization prior to preventive treatment with eptinezumab. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04152083. |
format | Online Article Text |
id | pubmed-9336038 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Milan |
record_format | MEDLINE/PubMed |
spelling | pubmed-93360382022-07-30 Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study Cady, Roger Lipton, Richard B. Buse, Dawn C. Josiassen, Mette Krog Lindsten, Annika Ettrup, Anders J Headache Pain Research BACKGROUND: The benefits of preventive treatment on the effectiveness of migraine management have rarely been examined. This post hoc analysis investigated the impact of eptinezumab on the optimization of acute medication effectiveness using the 4-item Migraine Treatment Optimization Questionnaire (mTOQ-4) to measure acute medication optimization over 4 weeks post-infusion. METHODS: RELIEF was a 12-week, phase 3, multicenter, parallel-group, double-blind, placebo-controlled clinical trial conducted in patients aged 18–75 years with a ≥ 1-year history of migraine and 4–15 migraine days per month in the 3 months prior to screening. Patients were randomized 1:1 to a 30-min infusion of eptinezumab 100 mg or placebo within 1–6 h of a qualifying migraine attack. The mTOQ-6 and 6-item Headache Impact Test (HIT-6) were administered at screening visit and week 4. From the mTOQ-6, we calculated the mTOQ-4 using the following items: “2-h pain free,” “24-h relief,” “able to plan,” and “feeling in control” to measure acute medication optimization. RESULTS: A total of 238 patients received eptinezumab 100 mg and 226 provided week 4 data; 242 received placebo and 232 provided week 4 data. In the eptinezumab arm, the proportion of patients with moderate/maximal optimization increased from 31.4% at baseline to 58.0% (26.6 percentage point increase) at week 4. The corresponding proportions in the placebo group were 40.5% to 50.4% (9.9 percentage point increase). Eptinezumab treatment was associated with numerically larger improvements in HIT-6 at week 4. Relative improvements with eptinezumab vs. placebo from baseline to week 4 in HIT-6 were greater in those with poor treatment optimization at baseline. CONCLUSIONS: In comparison with placebo, treatment with eptinezumab was associated with improvements in acute medication optimization as measured by mTOQ and reductions in headache impact, as measured by HIT-6. These benefits were greater in those with poor acute treatment optimization prior to preventive treatment with eptinezumab. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04152083. Springer Milan 2022-07-28 /pmc/articles/PMC9336038/ /pubmed/35902796 http://dx.doi.org/10.1186/s10194-022-01463-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Cady, Roger Lipton, Richard B. Buse, Dawn C. Josiassen, Mette Krog Lindsten, Annika Ettrup, Anders Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study |
title | Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study |
title_full | Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study |
title_fullStr | Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study |
title_full_unstemmed | Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study |
title_short | Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study |
title_sort | optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the relief study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336038/ https://www.ncbi.nlm.nih.gov/pubmed/35902796 http://dx.doi.org/10.1186/s10194-022-01463-3 |
work_keys_str_mv | AT cadyroger optimizationofacutemedicationusefollowingeptinezumabinitiationduringamigraineattackposthocanalysisofthereliefstudy AT liptonrichardb optimizationofacutemedicationusefollowingeptinezumabinitiationduringamigraineattackposthocanalysisofthereliefstudy AT busedawnc optimizationofacutemedicationusefollowingeptinezumabinitiationduringamigraineattackposthocanalysisofthereliefstudy AT josiassenmettekrog optimizationofacutemedicationusefollowingeptinezumabinitiationduringamigraineattackposthocanalysisofthereliefstudy AT lindstenannika optimizationofacutemedicationusefollowingeptinezumabinitiationduringamigraineattackposthocanalysisofthereliefstudy AT ettrupanders optimizationofacutemedicationusefollowingeptinezumabinitiationduringamigraineattackposthocanalysisofthereliefstudy |